Literature DB >> 6373441

Nimesulide in the treatment of fever: a double-blind, crossover clinical trial.

M Reiner, E Massera, E Magni.   

Abstract

A double-blind, crossover clinical trial was carried out in subjects with fever, to assess the activity of three antipyretic drugs. Eighteen in-patients with body temperature (axillary) above 38 degrees C were given a single dose of nimesulide 100 mg, acetylsalicylic acid 500 mg, and dipyrone 500 mg, orally according to an incomplete balanced block design. Significant improvement was recorded with nimesulide and dipyrone, which gave similar results. Acetylsalicylic acid normalized body temperature in a few patients. Safety was very satisfactory. No local or systemic side-effects were noted.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6373441     DOI: 10.1177/030006058401200207

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  6 in total

Review 1.  Nimesulide. A preliminary review of its pharmacological properties and therapeutic efficacy in inflammation and pain states.

Authors:  A Ward; R N Brogden
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

2.  Efficacy and tolerability of nimesulide and lysine-acetylsalicylate in the treatment of paediatric acute upper respiratory tract inflammation.

Authors:  L Cappella; A Guerra; L Laudizi; G B Cavazzuti
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 3.  Pyrazolone derivatives.

Authors:  R N Brogden
Journal:  Drugs       Date:  1986       Impact factor: 9.546

4.  Intramuscular Dipyrone versus Oral Ibuprofen or Nimesulide for Reduction of Fever in the Outpatient Setting.

Authors:  Hayri L Yilmaz; Nazan Alparslan; Dincer Yildizdas; Ibrahim Bayram; Emre Alhan
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

Review 5.  [Metamizole (dipyrone): mode of action, drug-drug interactions, and risk of agranulocytosis].

Authors:  C Lampl; R Likar
Journal:  Schmerz       Date:  2014-12       Impact factor: 1.107

6.  Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands.

Authors:  Hiroyuki Kohno; Rikako Suzuki; Shigeyuki Sugie; Takuji Tanaka
Journal:  BMC Cancer       Date:  2005-05-16       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.